0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha 4 beta 7

Integrin alpha 4 beta 7

Brief Information

Name:Integrin alpha-4/beta-7
Target Synonym:LPAM-1,Lymphocyte Peyer s patch Adhesion Molecule 1
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IT7-H52W4 Human Human Integrin alpha 4 beta 7 (ITGA4&ITGB7) Heterodimer Protein, His Tag&Tag Free
IT7-H52W4-structure
IT7-H52W4-sds
IT7-H52W4-elisa_1

Part of Bioactivity data

IT7-H52W4-SPR
Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag FreeHuman ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) ELISA bioactivity

Immobilized Natalizumab at 1 μg/mL (100 μL/well) can bind Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) with a linear range of 4-63 ng/mL (QC tested).

Synonym Name

Integrin alpha 4 beta 7,ITGA4&ITGB7

Background

Integrin alpha 4 beta 7 is an integrin family adhesion receptor that shares subunits with alpha 4 beta 1 (VLA4) and the E-Cadherin receptor, alpha E beta 7 . Integrin alpha 4 beta 7, which is critical for homing to intestinal mucosa, is induced during T cell activation in Peyer’s patches or mesenteric lymph nodes.Its expression requires signals from local dendritic and stromal cells, including secreted retinoic acid. The HIV-1 envelope protein gp120 binds to the active form of Integrin alpha 4 beta 7, and this may or may not account for the concentration of HIV-1 virus in the gut-associated lymphoid tissue (GALT). Integrin  alpha 4 beta 7 may also be involved in lymphocyte trafficking in acute intestinal graft vs. host disease (GVHD).

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Natalizumab BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E Approved Biogen Inc, Perrigo Tysabri, Antegran, Antegren Japan Multiple Sclerosis Biogen Inc 2004-11-23 Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Myeloma; Stroke; Crohn Disease Details
Vedolizumab LDP-02; LPD-02; MLN-02; MLN-002; MLN-0002 Approved Millennium Pharmaceuticals Inc 安吉优, Entyvio Mainland China Colitis, Ulcerative; Crohn Disease Takeda Pharma A/S 2014-05-20 Hematopoietic stem cell transplantation (HSCT); Inflammatory Bowel Diseases; Cholangitis, Sclerosing; Colitis, Ulcerative; Crohn Disease; Melanoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Natalizumab biosimilar (Polpharma Biologics) PB-006 Phase 3 Clinical Polpharma Biologics Multiple Sclerosis Details
PN-10943A PN-943; PN-10943; PN-10943-A Phase 2 Clinical Protagonist Therapeutics Inflammatory Bowel Diseases; Colitis, Ulcerative Details
Ontamalimab SHP-647; PF-547659; PF-00547659 Phase 3 Clinical Pfizer Inc Ileitis; Colitis, Ulcerative; Crohn Disease Details
Etrolizumab R-7413; RG-7413; PRO-145223; rhuMAb-Beta7 Phase 3 Clinical Genentech Inc Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease Details
MORF-057 MORF-057 Phase 1 Clinical Morphic Therapeutic Inflammatory Bowel Diseases Details

This web search service is supported by Google Inc.

totop